ClinicalIntelPulse · Clinical Mechanism MAP

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "drug_discovery_implications": "BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.",
  "first_in_class_opportunities": [
    "BTK inhibitors for progression (if Phase 3 data positive)",
    "Remyelinating agents (no approved class)"
  ],
  "key_publications": [
    {
      "journal": "Nature Reviews Neurology",
      "title": "BTK inhibitors in progressive MS — mechanisms and clinical data",
      "year": "2024"
    }
  ],
  "mechanism_landscape": {
    "approved_mechanisms": [
      {
        "drugs": [
          "Ocrelizumab",
          "Ofatumumab",
          "Ublituximab"
        ],
        "moa": "Anti-CD20 (B cell depletion)",
        "notes": "Dominant mechanism for RRMS — 3 approved"
      },
      {
        "drugs": [
          "Fingolimod",
          "Siponimod",
          "Ozanimod",
          "Ponesimod"
        ],
        "moa": "S1P receptor modulator",
        "notes": "Oral DMT — 4 approved; class mature"
      },
      {
        "drugs": [],
        "moa": "BTK inhibitor",
        "notes": "No approvals yet — 6 agents in Phase 2/3"
      }
    ],
    "crowded_spaces": [
      "Anti-CD20 (3 approved, 2 in pipeline)",
      "S1P modulators (4 approved)",
      "Natalizumab analogues"
    ],
    "pipeline_mechanisms": [
      {
        "agents": [
          "Fenebrutinib (Roche)",
          "Tolebrutinib (Sanofi)",
          "Evobrutinib (Merck)"
        ],
        "crowding": "Moderate (3 Phase 3)",
        "differentiation": "Targets microglial activation — may address progressive MS unlike existing agents",
        "moa": "BTK inhibition (CNS-penetrant)",
        "phase": "PHASE3"
      },
      {
        "agents": [
          "Opicinumab (Biogen)"
        ],
        "crowding": "Low",
        "differentiation": "Novel — no approved remyelinating agents",
        "moa": "Remyelination (opioid receptor modulation)",
        "phase": "PHASE2"
      }
    ],
    "white_spaces": [
      "Progressive MS neuroprotection",
      "Remyelination",
      "CNS innate immunity",
      "Biomarker-stratified precision approaches"
    ]
  },
  "query_summary": {
    "condition": "Multiple Sclerosis",
    "mechanism": null
  }
}